SPIRAL II Project (electron option) - Preliminary Design Study

This document presents a Preliminary Design Study (PDS) of the electron option of the SPIRAL II project

GANIL status report

International audienceGANIL operation has been orientated towards an increase of intensities these last years, for production of both radioactive beams by fragmentation through SISSI device and exotic nuclei in the experimental caves, and in view of Spiral start up. Usual running statistics are presented, as well as the operation conditions and results in terms of beam intensities. Different improvements and equipment renovations have been realized consequently: beam production method developments on the ECR sources, hard-ware renovations, tuning and control programs, development of high intensity beam diagnostics. A review of these works is reported

Experience with high intensity operation of the GANIL facility

International audienceThe GANIL three stage accelerator facility is being upgraded to higher beam intensities for light projectiles (C to Ar). in view of the production and acceleration of radioactive ion beams by the SPIRAL complex. intensities of the order of I to 2x10l3 pps are anticipated at the maximum energy of 95 MeV/u. The status of the upgrading program is summarised and details on the hardware and software additions and modifications are given. At the SSCI ejection energy. the design goal could be reached. As for SSC2, several factors are presently limiting the output current to 5x1012 pps. Operational experience and solutions to reach the design goal are reported

The EUNEASO Project: A European NEO Search, Follow-up and Physical Observation Programme

EUNEASO, which stands for EUropean Near-Earth Asteroids Search Observatories, is a cooperation to organize a large-scale NEO search programme. The participating groups do astrometric follow-up observations as well as photometric and spectroscopic studies of NEO's. Currently, the development of CCD cameras for the search programme is done at the DLR in Berlin and the OCA in Nice, where tests have been performed with the 90 cm Schmidt telescope at Caussols. Scanning photographic films taken by a Schmidt telescope appears to be a promising tool to detect NEO's. Corresponding tests with commercial scanners are carried out at OCA. Plans exist to install a 1.5 k x lk CCD at the 67 cm Schmidt telescope in Asiago, Italy. Astrometric follow-up and photometric observations of NEO's are currently done on a routine basis at Ondrejov Observatory, Czech Republic, using a 60 cm telescope equipped with a CCD camera. A similar system is available at Kharkiv Observatory, Ukraine, attached to a 70 cm telescope. Photometric CCD observations of NEO's are performed as part of the asteroid observing programme of the DLR with the 60 cm Bochum telescope at ESO, which is available for some 100 nights per year

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology